LAVA THERAPEUTICS
Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of hematological and solid cancers. Its platform creates and develops next-generation γδ T cell engaging bispecific antibodies for the treatment of cancer as well as develop potent, safe, and cost-effective biopharmaceuticals that arm the immune system to recognize and destroy tumor cells that enable doctors to safely channel the immune system's response towards tumors.
LAVA THERAPEUTICS
Industry:
Biotechnology Life Science Medical Medical Device
Founded:
2016-01-01
Address:
Utrecht, Utrecht, The Netherlands
Country:
The Netherlands
Website Url:
http://www.lavatherapeutics.com
Total Employee:
51+
Status:
Active
Contact:
+31 8 506 573 44
Email Addresses:
[email protected]
Total Funding:
102.85 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Domain Not Resolving Global Site Tag Sitelinks Search Box
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Dice Therapeutics
Dice Therapeutics develops a transformative platform designed for the discovery of novel small molecules.
Numab
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
Ontera
Ontera develops a hand-held point of use diagnostic platform that examines DNA and RNA, and analytes from any life form.
Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
SpyBiotech
SpyBiotech Operators of a biotechnology platform intended to generate next-generation vaccines.
T-knife
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.
Transine Therapeutics
Transine Therapeutics is a developer of biotech platform enhancing therapeutics for the treatment of human disease.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Sanofi Ventures
Sanofi Ventures investment in Series C - Lava Therapeutics
Versant Ventures
Versant Ventures investment in Series C - Lava Therapeutics
Novo Ventures
Novo Ventures investment in Series C - Lava Therapeutics
Gilde Healthcare
Gilde Healthcare investment in Series C - Lava Therapeutics
Pureos Bioventures
Pureos Bioventures investment in Series C - Lava Therapeutics
Ysios Capital
Ysios Capital investment in Series C - Lava Therapeutics
Redmile Group
Redmile Group investment in Series C - Lava Therapeutics
MRL Ventures Fund
MRL Ventures Fund investment in Series C - Lava Therapeutics
Kinled Holding
Kinled Holding investment in Series A - Lava Therapeutics
Versant Ventures
Versant Ventures investment in Series A - Lava Therapeutics
Official Site Inspections
http://www.lavatherapeutics.com Semrush global rank: 9.13 M Semrush visits lastest month: 208
- Host name: 154.18.109.208.host.secureserver.net
- IP address: 208.109.18.154
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Lava Therapeutics"
Lava Therapeutics
May 21, 2024 · Our novel Gammabody ® platform generates bispecific gamma delta T cell engager therapeutics that activate a unique and relatively abundant effector gamma delta T …See details»
Company Overview - Lava Therapeutics
To date, we are the only company developing bispecific gamma delta T cell engaging antibodies for the treatment of cancer. Lava is focused on applying expertise in gamma-delta T cell …See details»
LAVA Therapeutics N.V. | LinkedIn
At LAVA, we are focused on applying our expertise in gamma-delta T-cell engagers (TCEs) to transform cancer therapy. We refer to our compounds as gamma-delta bispecific T-cell …See details»
LAVA Therapeutics N.V. | LinkedIn
At LAVA, we are focused on applying our expertise in gamma-delta T-cell engagers (TCEs) to transform cancer therapy. We refer to our compounds as gamma-delta bispecific T-cell engagers, or...See details»
LAVA Therapeutics Announces $83 million Series C Financing to …
Sep 17, 2020 · LAVA Therapeutics, a biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer therapies, today announced the closing …See details»
Lava Therapeutics - Crunchbase Company Profile
Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of cancer. Lava Therapeutics announced a collaboration with Merck & Co., Inc. to evaluate LAVA-1207 in combination …See details»
Corporate Governance - LAVA Therapeutics N.V.
Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the …See details»
News Release - LAVA Therapeutics N.V.
Jun 14, 2023 · LAVA-1207 is a Gammabody designed to target the prostate-specific membrane antigen (PSMA) to trigger the potent and preferential killing of PSMA-positive tumor cells in …See details»
Events - LAVA Therapeutics N.V.
Stephen Hurly, President and Chief Executive Officer at LAVA Therapeutics, will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, …See details»
Lava Therapeutics - Overview, News & Similar companies
Jun 8, 2023 · View Lava Therapeutics (www.lavatherapeutics.com) location in Utrecht, Netherlands , revenue, industry and description. Find related and similar companies as well as …See details»
Careers - Lava Therapeutics
At LAVA, we are committed to the growth and development of our employees. Every member of our family has a story about their experiences. Hear what they have to say! Ashwini, Associate Director Regulatory-CMC, joined LAVA in 2021.See details»
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc ...
Jan 25, 2024 · Under the terms of the agreement, Merck & Co., Inc., Rahway, NJ, USA will provide pembrolizumab for the dose escalation and expansion phases of LAVA’s ongoing …See details»
LAVA Therapeutics Provides Business Update and Reports First …
Jun 8, 2023 · About LAVA Therapeutics LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on developing its proprietary Gammabodyâ„¢ platform to develop a …See details»
Lava Therapeutics Raises EUR 16 Million to Advance Bispecific …
May 23, 2018 · Lava’s vision is to develop therapeutics for the curative treatment of cancer. Founded in 2016, Lava Therapeutics is advancing cutting-edge research originating from the …See details»
LAVA Therapeutics Announces Treatment of First Patient in
Feb 1, 2022 · LAVA Therapeutics N.V. is an immuno-oncology company utilizing its proprietary Gammabodyâ„¢ platform to develop a portfolio of bispecific gamma delta T cell engagers …See details»
LAVA Therapeutics Receives FDA Orphan Drug Designation for
Oct 15, 2021 · LAVA Therapeutics N.V. is a clinical-stage biotechnology company utilizing its proprietary Gammabodyâ„¢ platform to develop a portfolio of bispecific gamma delta T cell …See details»
LAVA Therapeutics and The Antibody Society Present Emerging …
Nov 11, 2021 · LAVA Therapeutics N.V. is a clinical-stage biotechnology company utilizing its proprietary Gammabodyâ„¢ platform to develop a portfolio of bispecific gamma delta T cell …See details»
Pipeline - Lava Therapeutics
Our lead program, LAVA-051, is a unique, humanized gamma-delta bsTCE targeting CD1d-expressing tumors, including multiple myeloma, chronic lymphocytic leukemia (CLL), and …See details»
LAVA Therapeutics N.V. (LVTX) - Stock Analysis
Get a real-time LAVA Therapeutics N.V. (LVTX) stock price quote with breaking news, financials, statistics, charts and more.See details»
News Release - LAVA Therapeutics N.V.
LAVA Therapeutics B.V. is a biotechnology company developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and …See details»